Physician profile
Daniel G Luba
NPI 1790786002
$2,623.71
in general payments reported to CMS, 2019-2025
33 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $196 · 2021: $263 · 2022: $707 · 2023: $158 · 2024: $214 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578 · Education: $15.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.80 |
| Education | $15.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $751.92 | 2019-2025 | |
| Gilead Sciences, INC. | $342.33 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.07 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $178.18 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Pentax of America, INC. | $158.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.18 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $100.00 | 2022 | |
| Cook Medical LLC | $78.86 | 2019 | |
| Ironwood Pharmaceuticals, INC | $66.44 | 2019 | |
| Intercept Pharmaceuticals, INC. | $57.49 | 2022-2024 | |
| Pfizer INC. | $57.18 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $55.00 | 2024-2025 | Iqirvo |
| Romark Laboratories, Lc | $32.35 | 2019 | |
| Qol Medical, LLC | $28.08 | 2019-2022 | |
| Vivus LLC | $26.39 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $25.67 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $24.04 | 2019 | |
| Braintree Laboratories, INC. | $23.73 | 2019-2021 | |
| Alfasigma USA, INC. | $23.30 | 2020 | |
| Daiichi Sankyo INC. | $23.23 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $23.21 | 2020 | |
| Avanir Pharmaceuticals, INC. | $22.62 | 2022 | |
| Olympus America INC. | $22.07 | 2022 | |
| Ardelyx, INC. | $20.26 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $19.71 | 2023 | Dificid |
| Janssen Pharmaceuticals, INC | $18.59 | 2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $15.72 | 2024 | Voquezna |
| Celltrion USA INC. | $15.40 | 2024 | Zymfentra |
| Endo Pharmaceuticals INC. | $15.09 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.70 | 2022 | |
| Allergan, INC. | $14.28 | 2019 | |
| Medtronic, INC. | $13.11 | 2024 | Gi Genius |
| Lilly USA, LLC | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Luba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.